Oil prices dip on fears of slowing demand, oversupply
SAN DIEGO - Gyre Therapeutics (NASDAQ:GYRE), a commercial-stage biopharmaceutical company focused on fibrosis therapies with a market capitalization of $682.53 million, announced today the appointment of Dan Weng, M.D., to its Board of Directors, effective August 18, 2025.
Dr. Weng currently serves as President and Chief Executive Officer of Medelis, Inc., a specialty oncology contract research organization. His experience includes leadership roles at several clinical research organizations, including serving as Chairman, President, and CEO of EPS International Holding Co. from 2013 to 2017.
Prior to his current position, Dr. Weng held executive positions at MedPace, ICON, PharmaNet Development Group, and Quintiles Translational Corp. His academic background includes research positions at Harvard Medical School, Massachusetts General Hospital, and the University of California.
Dr. Weng holds an M.D. from Tongji Medical University and an M.A. in Health Planning, Policy and Management from the University of Leeds.
Ping Zhang, Executive Chairman and Interim CEO of Gyre, stated that Dr. Weng brings nearly four decades of experience in managing global clinical trials across various therapeutic areas.
Gyre Therapeutics is headquartered in San Diego and focuses on developing Hydronidone for liver fibrosis in the United States. The company maintains an indirect controlling interest in Gyre Pharmaceuticals, which markets ETUARY (Pirfenidone capsule), a treatment for IPF first approved in China in 2011. The company demonstrates strong financial health with a remarkable 95.91% gross profit margin and a healthy current ratio of 5.4, indicating robust liquidity. InvestingPro analysis reveals 8 additional key financial insights available to subscribers.
According to the company’s press release, Gyre Pharmaceuticals is also developing Hydronidone for CHB-associated liver fibrosis, with NDA filing expected in the third quarter of 2025. Trading at $7.55, the stock has attracted strong analyst interest with a unanimous Buy rating and appears undervalued according to InvestingPro Fair Value metrics.
In other recent news, Gyre Therapeutics has announced a public offering of 2,222,222 shares of common stock at $9.00 each, under an underwriting agreement with Jefferies LLC. The company expects to raise approximately $18.5 million from this offering, with the option for underwriters to purchase an additional 333,333 shares within 30 days. The proceeds are earmarked for advancing the Phase 2 clinical trial of F351, a treatment for liver fibrosis related to metabolic dysfunction-associated steatohepatitis in the United States, as well as for research and development, manufacturing, and general corporate purposes. In another development, Gyre Therapeutics reported positive results from a Phase 3 trial in China for its drug candidate, Hydronidone, which targets liver fibrosis in patients with chronic hepatitis B. The trial demonstrated a significant regression in liver fibrosis among patients treated with Hydronidone compared to those on a placebo. The study involved 248 patients and was conducted over 52 weeks across 39 hospitals, with 52.85% of patients in the Hydronidone group achieving a ≥1-stage fibrosis regression. These developments highlight Gyre Therapeutics’ ongoing efforts in advancing treatments for liver fibrosis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.